These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24305957)

  • 21. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
    Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
    Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.
    Spearman P
    Curr Top Med Chem; 2016; 16(10):1154-66. PubMed ID: 26329615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility.
    Williams A; Basson A; Achilonu I; Dirr HW; Morris L; Sayed Y
    Biochem J; 2019 Jan; 476(2):375-384. PubMed ID: 30573649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C.
    Ghimire D; Timilsina U; Srivastava TP; Gaur R
    Sci Rep; 2017 Mar; 7():43711. PubMed ID: 28252110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
    van Maarseveen NM; Andersson D; Lepšík M; Fun A; Schipper PJ; de Jong D; Boucher CA; Nijhuis M
    Retrovirology; 2012 Apr; 9():29. PubMed ID: 22462820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
    Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
    J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conformation and dynamics of the Gag polyprotein of the human immunodeficiency virus 1 studied by NMR spectroscopy.
    Deshmukh L; Ghirlando R; Clore GM
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3374-9. PubMed ID: 25713345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation.
    Tedbury PR; Novikova M; Alfadhli A; Hikichi Y; Kagiampakis I; KewalRamani VN; Barklis E; Freed EO
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding kinetics and substrate selectivity in HIV-1 protease-Gag interactions probed at atomic resolution by chemical exchange NMR.
    Deshmukh L; Tugarinov V; Louis JM; Clore GM
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):E9855-E9862. PubMed ID: 29087351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
    Wu X; Liu H; Xiao H; Kappes JC
    Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein.
    Zentner I; Sierra LJ; Fraser AK; Maciunas L; Mankowski MK; Vinnik A; Fedichev P; Ptak RG; Martín-García J; Cocklin S
    ChemMedChem; 2013 Mar; 8(3):426-32. PubMed ID: 23361947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of A Fission Yeast Cell-Based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.
    Benko Z; Zhang J; Zhao RY
    Curr HIV Res; 2019; 17(6):429-440. PubMed ID: 31782368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease.
    Serio D; Singh SP; Cartas MA; Weber IT; Harrison RW; Louis JM; Srinivasan A
    Protein Eng; 2000 Jun; 13(6):431-6. PubMed ID: 10877854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions.
    Huang L; Li Y; Chen C
    Retrovirology; 2011 Oct; 8():79. PubMed ID: 21985091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396.
    Murgatroyd C; Pirrie L; Tran F; Smith TK; Westwood NJ; Adamson CS
    J Virol; 2016 Sep; 90(18):8181-97. PubMed ID: 27384665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.
    Kozísek M; Henke S; Sasková KG; Jacobs GB; Schuch A; Buchholz B; Müller V; Kräusslich HG; Rezácová P; Konvalinka J; Bodem J
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4320-30. PubMed ID: 22644035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.
    Wu X; Liu H; Xiao H; Conway JA; Kappes JC
    J Virol; 1996 Jun; 70(6):3378-84. PubMed ID: 8648668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen.
    Prado S; Beltrán M; Coiras M; Bedoya LM; Alcamí J; Gallego J
    Biochem Pharmacol; 2016 May; 107():14-28. PubMed ID: 26896646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.